Analysis of Related Factors of Hypophosphatemic Osteomalacia Induced by Adefovir Dipivoxil

Abstract

Abstract: Objective To analyze the characteristics and related factors of hypophosphatemic osteomalacia induced by adefovir dipivoxil. Methods Cases treated by anti-hepatitis B drugs from 6 tertiary comprehensive hospitals were investigated retrospectively. The status of drug use, age, sex, medication, adverse drug reactions and treatment outcomes were analyzed descriptively. Results Anti-hepatitis B virus with adefovir dipivoxil may cause osteomalacia hypophosphatemia. The changes in renal function-related biochemical indicators, such as blood phosphorus, urinary phosphorus and creatinine, are the early indications. Hypophosphatemia usually occurs 3~5 years after treatment beginning, and the changes in renal function-related biochemical indicators mainly involved were blood phosphorus, urinary phosphorus, creatinine, etc. Patients with advanced age, poor nutritional status, and chronic liver and kidney diseases are easier to develop the adverse reaction. Conclusion For the patients treated by adefovir, clinicians should fully understand this adverse reaction, and should regularly monitor renal function and serum phosphorus. Patients with poor nutrition and with history of kidney disease should be monitored more strongly.

Key words: adefovir dipivoxil, hypophosphatemic osteomalacia, retrospective analysis

CLC Number:

R994.11

XIE Yanjun, WU Guizhi, XU Lili, CUI Xiaokang, LU Changfei, TIAN Yuejie. Analysis of Related Factors of Hypophosphatemic Osteomalacia Induced by Adefovir Dipivoxil[J]. Chinese Journal of Pharmacovigilance, 2018, 15(11): 668-673.

References

[1] 王俊娜,黄文祥.77例阿德福韦酯致范可尼综合征回顾性分析[J].中国新药杂志,2016,25(19):2277-2280.
[2] 李璐,宋红松,蔡皓东.阿德福韦酯相关范科尼综合征合并脊髓病及周围神经病[J].药物不良反应杂志,2014,16(1):52-53.
[3] 王全楚,常慧,王东琳.长期超量服用阿德福韦酯引起范可尼综合征1例[J].实用肝脏病杂志,2013,6(2):168.
[4] 陆明晰,吕芳芳,苏关关,等.阿德福韦酯相关性肾小管病四例[J].中华传染病杂志,2013,31(8):1499-500.
[5] 赵攀, 赵沐缙, 吴永杰. 恩替卡韦与阿德福韦酯治疗慢性乙肝所致不良反应情况的比较[J]. 中国药物应用与监测, 2010, 22(5): 261-262,278.
[6] 颜淑敏, 张娟, 李宏超, 等. 低剂量阿德福韦酯致低血磷性骨软化症的临床特点及治疗分析[J]. 中国全科医学, 2013,20(26): 2350-2353.
[7] Lee H J, Choi J W, Kim T N, et al.A case of severe hypophosphatemia related to adefovir dipivoxil treatment in a patient with liver cirrhosis related to hepatitis B virus[J]. Korean J Hepatol, 2008, 14(3):381-386.
[8] Jung Y K, Yeon J E, Choi J H, et al.Fanconi's syndrome associated with prolonged adefovir dipivoxil therapy in a hepatitis B virus patient[J]. Gut Liver, 2010,4(3):389-393.
[9] Kwon S Y, Ahn S Y, Ko S Y, et al.A case of osteomalacia related to adefovir in a patient with chronic hepatitis B[J]. Korean J Gastroenterol, 2010,56(2):117-120.
[10] Minemura M, Tokimitsu Y, Tajiri K, et al.Development of osteomalacia in a post-liver transplant patient receiving adefovir dipivoxil[J].World J Hepatol, 2010, 2(12):442-446.
[11] 田月洁, 王金英, 谢彦军, 等. 阿德福韦酯治疗乙肝致低血磷性骨软化症的现状分析[J]. 中国药物警戒, 2013, 10(5):294-298.
[12] Cihlar T,Lin D C,Pritchard J B,et al.The antiviral nucleotide analogs eidofovir and adefovir are novel substrates for human and rat renal organic anion transporter[J]. Mol Pharmacol ,1999,56(3): 570-580.
[13] Ho E S,Lin D C Mendel D B,et al.Cytotoxicity of antiviral nucleotides adefovir and eidofovir is induced by the expression of human renal organic anion transporter[J]. JAm Soc Nephrol,2000
11(3):383-393.
[14] 许莉莉, 田月洁, 谢彦军,等.160例阿德福韦酯不良反应特征及骨软化的风险因素分析[J]. 中国药物警戒, 2015,12(8): 487-490.
[15] 徐炼红. 阿德福韦酯对慢性乙型肝炎患者血磷代谢的影响观察及其相关因素分析[J]. 中国实用医药,2017,12(23):125-126.
[17] 赵守松,余晓阳. 慢性乙型肝炎患者肾脏安全问题[J]. 肝博士,2017, (4):44-45.
[18] 袁乐媛,王柏芳,王炳元,等.阿德福韦酯诱发范可尼综合征和骨软化症病例报告和误诊分析[J].传染病信息,2013,26(2) 117-119.